Patents by Inventor Julie A. Kelly
Julie A. Kelly has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11984196Abstract: Disclosed are techniques for characterizing variants of interest and predicting assignments of individuals to communities based on obtained genetic information. To characterize a variant, DNA datasets of reference individuals are accessed and used to generate a cluster with additional individuals. Reference individuals carry a variant at a genetic locus and the additional individuals share IBD with reference individuals. Statistics of genealogical data of the cluster are generated. A result summarizing the characterization of the variant is generated based on the statistics. To determine if an individual belongs to a community, a subset of the individual's haplotypes are inputted into a community-specific model. The model is trained using the training samples that each include haplotypes of reference individuals and a label identifying whether the reference individual belongs to the community. Based on the output of the model, it is determined whether the individual is a member of the community.Type: GrantFiled: November 19, 2021Date of Patent: May 14, 2024Assignee: ANCESTRY.COM DNA, LLCInventors: Jake Kelly Byrnes, Julie M. Granka, Shannon Hateley, Ladan Doroud
-
Publication number: 20230173333Abstract: Examples of an exercise mat and methods for making same are disclosed. The exercise mat comprises a top layer, at least two textured gripping zones formed on an upper surface of the top layer and a bottom layer joined to the top layer. A second textured gripping zone of the at least two textured gripping zones may be formed closer to one or more mat edges of the exercise mat, and has a friction level that is greater than a friction level of a first textured gripping zone of the at least two textured gripping zones, when a body is in sliding contact with the at least two textured gripping zones of the upper surface of the top layer.Type: ApplicationFiled: November 29, 2022Publication date: June 8, 2023Inventors: Colton Kai YU, Laura Julie KELLY, Miguel Angel HERRERA MACIAS, Josh Nehru Samonte Delfin, Kate Alexandria MACMILLAN, Adrian Ka Ming LAI, Jemon LIN
-
Patent number: 9873717Abstract: The invention relates to a novel thyrotropin releasing hormone (TRH) receptor subtype in human central nervous system (CNS) that is pharmacologically distinct from the TRH receptor subtype in human pituitary. The invention provides a means to understand how the central actions of TRH are mediated and to isolate and characterize the novel receptor, as well as methods applicable to research and development of diagnostic and therapeutic applications in human CNS disorders.Type: GrantFiled: December 18, 2013Date of Patent: January 23, 2018Assignee: THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLINInventor: Julie Kelly
-
Patent number: 9506074Abstract: The present invention relates to recombinant microorganisms comprising biosynthetic pathways and methods of using said recombinant microorganisms to produce various beneficial metabolites. In various aspects of the invention, the recombinant microorganisms may further comprise one or more modifications resulting in the reduction or elimination of 3 keto-acid (e.g., acetolactate and 2-aceto-2-hydroxybutyrate) and/or aldehyde-derived by-products. In various embodiments described herein, the recombinant microorganisms may be microorganisms of the Saccharomyces Glade, Crabtree-negative yeast microorganisms, Crabtree-positive yeast microorganisms, post-WGD (whole genome duplication) yeast microorganisms, pre-WGD (whole genome duplication) yeast microorganisms, and non-fermenting yeast microorganisms.Type: GrantFiled: September 19, 2013Date of Patent: November 29, 2016Assignee: GEVO, INC.Inventors: Thomas Buelter, Andrew Hawkins, Stephanie Porter-Scheinman, Peter Meinhold, Catherine Asleson Dundon, Aristos Aristidou, Jun Urano, Doug Lies, Matthew Peters, Melissa Dey, Justas Jancauskas, Julie Kelly, Ruth Berry
-
Publication number: 20150361136Abstract: The invention relates to a novel thyrotropin releasing hormone (TRH) receptor subtype in human central nervous system (CNS) that is pharmacologically distinct from the TRH receptor subtype in human pituitary. The invention provides a means to understand how the central actions of TRH are mediated and to isolate and characterise the novel receptor, as well as methods applicable to research and development of diagnostic and therapeutic applications in human CNS disorders.Type: ApplicationFiled: December 18, 2013Publication date: December 17, 2015Inventor: Julie Kelly
-
Publication number: 20140212953Abstract: The present invention relates to recombinant microorganisms comprising biosynthetic pathways and methods of using said recombinant microorganisms to produce various beneficial metabolites. In various aspects of the invention, the recombinant microorganisms may further comprise one or more modifications resulting in the reduction or elimination of 3 keto-acid (e.g., acetolactate and 2-aceto-2-hydroxybutyrate) and/or aldehyde-derived by-products. In various embodiments described herein, the recombinant microorganisms may be microorganisms of the Saccharomyces Glade, Crabtree-negative yeast microorganisms, Crabtree-positive yeast microorganisms, post-WGD (whole genome duplication) yeast microorganisms, pre-WGD (whole genome duplication) yeast microorganisms, and non-fermenting yeast microorganisms.Type: ApplicationFiled: September 19, 2013Publication date: July 31, 2014Applicant: GEVO, Inc.Inventors: Thomas BUELTER, Andrew Hawkins, Stephanie Porter-Scheinman, Peter Meinhold, Catherine Asleson Dundon, Aristos Aristidou, Jun Urano, Doug Lies, Matthew Peters, Melissa Dey, Justas Jancauskas, Kent Evans, Julie Kelly, Ruth Berry
-
Patent number: 8158404Abstract: The present invention relates to recombinant microorganisms comprising biosynthetic pathways and methods of using said recombinant microorganisms to produce various beneficial metabolites. In various aspects of the invention, the recombinant microorganisms may further comprise one or more modifications resulting in the reduction or elimination of 3 keto-acid (e.g., acetolactate and 2-aceto-2-hydroxybutyrate) and/or aldehyde-derived by-products. In various embodiments described herein, the recombinant microorganisms may be microorganisms of the Saccharomyces clade, Crabtree-negative yeast microorganisms, Crabtree-positive yeast microorganisms, post-WGD (whole genome duplication) yeast microorganisms, pre-WGD (whole genome duplication) yeast microorganisms, and non-fermenting yeast microorganisms.Type: GrantFiled: March 30, 2011Date of Patent: April 17, 2012Assignee: Gevo, Inc.Inventors: Doug Lies, Stephanie Porter-Scheinman, Julie Kelly, Catherine Asleson Dundon, Aristos Aristidou, Andrew Hawkins
-
Patent number: 8153415Abstract: The present invention relates to recombinant microorganisms comprising biosynthetic pathways and methods of using said recombinant microorganisms to produce various beneficial metabolites. In various aspects of the invention, the recombinant microorganisms may further comprise one or more modifications resulting in the reduction or elimination of 3 keto-acid (e.g., acetolactate and 2-aceto-2-hydroxybutyrate) and/or aldehyde-derived by-products. In various embodiments described herein, the recombinant microorganisms may be microorganisms of the Saccharomyces clade, Crabtree-negative yeast microorganisms, Crabtree-positive yeast microorganisms, post-WGD (whole genome duplication) yeast microorganisms, pre-WGD (whole genome duplication) yeast microorganisms, and non-fermenting yeast microorganisms.Type: GrantFiled: March 31, 2011Date of Patent: April 10, 2012Assignee: Gevo, Inc.Inventors: Thomas Buelter, Andrew Hawkins, Stephanie Porter-Scheinman, Peter Meinhold, Catherine Asleson Dundon, Aristos Aristidou, Jun Urano, Doug Lies, Matthew Peters, Melissa Dey, Justas Jancauskas, Julie Kelly, Ruth Berry
-
Patent number: 8133715Abstract: The present invention relates to recombinant microorganisms comprising biosynthetic pathways and methods of using said recombinant microorganisms to produce various beneficial metabolites. In various aspects of the invention, the recombinant microorganisms may further comprise one or more modifications resulting in the reduction or elimination of 3 keto-acid (e.g., acetolactate and 2-aceto-2-hydroxybutyrate) and/or aldehyde-derived by-products. In various embodiments described herein, the recombinant microorganisms may be microorganisms of the Saccharomyces clade, Crabtree-negative yeast microorganisms, Crabtree-positive yeast microorganisms, post-WGD (whole genome duplication) yeast microorganisms, pre-WGD (whole genome duplication) yeast microorganisms, and non-fermenting yeast microorganisms.Type: GrantFiled: March 29, 2011Date of Patent: March 13, 2012Assignee: Gevo, Inc.Inventors: Thomas Buelter, Andrew Hawkins, Stephanie Porter-Scheinman, Peter Meinhold, Catherine Asleson Dundon, Aristos Aristidou, Jun Urano, Matthew Peters, Melissa Dey, Justas Jancauskas, Julie Kelly, Ruth Berry
-
Publication number: 20110275129Abstract: The present invention relates to recombinant microorganisms comprising biosynthetic pathways and methods of using said recombinant microorganisms to produce various beneficial metabolites. In various aspects of the invention, the recombinant microorganisms may further comprise one or more modifications resulting in the reduction or elimination of 3 keto-acid (e.g., acetolactate and 2-aceto-2-hydroxybutyrate) and/or aldehyde-derived by-products. In various embodiments described herein, the recombinant microorganisms may be microorganisms of the Saccharomyces clade, Crabtree-negative yeast microorganisms, Crabtree-positive yeast microorganisms, post-WGD (whole genome duplication) yeast microorganisms, pre-WGD (whole genome duplication) yeast microorganisms, and non-fermenting yeast microorganisms.Type: ApplicationFiled: March 29, 2011Publication date: November 10, 2011Applicant: GEVO, INC.Inventors: Thomas Buelter, Andrew Hawkins, Stephanie Porter-Scheinman, Peter Meinhold, Catherine Asleson Dundon, Aristos Aristidou, Jun Urano, Matthew Peters, Melissa Dey, Justas Jancauskas, Julie Kelly, Ruth Berry
-
Publication number: 20110236942Abstract: The present invention relates to recombinant microorganisms comprising biosynthetic pathways and methods of using said recombinant microorganisms to produce various beneficial metabolites. In various aspects of the invention, the recombinant microorganisms may further comprise one or more modifications resulting in the reduction or elimination of 3 keto-acid (e.g., acetolactate and 2-aceto-2-hydroxybutyrate) and/or aldehyde-derived by-products. In various embodiments described herein, the recombinant microorganisms may be microorganisms of the Saccharomyces clade, Crabtree-negative yeast microorganisms, Crabtree-positive yeast microorganisms, post-WGD (whole genome duplication) yeast microorganisms, pre-WGD (whole genome duplication) yeast microorganisms, and non-fermenting yeast microorganisms.Type: ApplicationFiled: March 30, 2011Publication date: September 29, 2011Applicant: GEVO, INC.Inventors: Andrew Hawkins, Stephanie Porter-Scheinman, Catherine Asleson Dundon, Aristos Aristidou, Doug Lies, Julie Kelly
-
Publication number: 20110201090Abstract: The present invention relates to recombinant microorganisms comprising biosynthetic pathways and methods of using said recombinant microorganisms to produce various beneficial metabolites. In various aspects of the invention, the recombinant microorganisms may further comprise one or more modifications resulting in the reduction or elimination of 3 keto-acid (e.g., acetolactate and 2-aceto-2-hydroxybutyrate) and/or aldehyde-derived by-products. In various embodiments described herein, the recombinant microorganisms may be microorganisms of the Saccharomyces clade, Crabtree-negative yeast microorganisms, Crabtree-positive yeast microorganisms, post-WGD (whole genome duplication) yeast microorganisms, pre-WGD (whole genome duplication) yeast microorganisms, and non-fermenting yeast microorganisms.Type: ApplicationFiled: February 11, 2011Publication date: August 18, 2011Applicant: GEVO, INC.Inventors: Thomas Buelter, Andrew Hawkins, Stephanie Porter-Scheinman, Peter Meinhold, Catherine Asleson Dundon, Aristos Aristidou, Jun Urano, Doug Lies, Matthew Peters, Melissa Dey, Justas Jancauskas, Kent Evans, Julie Kelly, Ruth Berry
-
Publication number: 20110201073Abstract: The present invention relates to recombinant microorganisms comprising biosynthetic pathways and methods of using said recombinant microorganisms to produce various beneficial metabolites. In various aspects of the invention, the recombinant microorganisms may further comprise one or more modifications resulting in the reduction or elimination of 3 keto-acid (e.g., acetolactate and 2-aceto-2-hydroxybutyrate) and/or aldehyde-derived by-products. In various embodiments described herein, the recombinant microorganisms may be microorganisms of the Saccharomyces clade, Crabtree-negative yeast microorganisms, Crabtree-positive yeast microorganisms, post-WGD (whole genome duplication) yeast microorganisms, pre-WGD (whole genome duplication) yeast microorganisms, and non-fermenting yeast microorganisms.Type: ApplicationFiled: March 31, 2011Publication date: August 18, 2011Applicant: GEVO, INC.Inventors: Thomas Buelter, Andrew Hawkins, Stephanie Porter-Scheinman, Peter Meinhold, Catherine Asleson Dundon, Aristos Aristidou, Jun Urano, Doug Lies, Matthew Peters, Melissa Dey, Justas Jancauskas, Julie Kelly, Ruth Berry
-
Patent number: 7713935Abstract: The invention relates to compounds that inhibit thyrotropin-releasing hormone (TRH) degrading ectoenzyme and/or enhance, and/or mimic the biological actions of TRH. The compounds find therapeutic application, particularly in conditions involving neuronal cell injury and disturbances in neurobiological function.Type: GrantFiled: October 3, 2005Date of Patent: May 11, 2010Assignee: The Provost, Fellows and Scholars of The College of The Holy and Undivided Trinity of Queen Elizabeth Near DublinInventor: Julie Kelly
-
Patent number: 7378397Abstract: Peptide derivatives useful as inhibitors of activity of thyrotropin-releasing hormone-degrading ectoenzyme (TRH-DE) are of formula Ia: wherein: R1 is an optionally substituted 4-, 5- or 6-membered heterocyclic ring having one or more heteroatoms, in which at least one carbon atom of the ring is substituted with O or S; X1 is —CO— or —CS— or —CH2CO— or CH(R4) wherein R4 is H or optionally substituted alkyl or —COOH or —COOR11 wherein R11 is optionally substituted alkyl; X2 and X3 (which may be the same or different) are —CO— or —CS—; Z is —CH2— or —S— or —O— or —NH—; Q is O or S; R2 is H or optionally substituted alkyl or an optionally substituted carbocyclic ring; R3 is H or optionally substituted alkyl or an optionally substituted mono- or polycyclic ring, optionally having one or more heteroatoms in the ring(s) and optionally being a fused ring; or R2 and R3 together form an optionally substituted mono- or polycyclic ring optionally having one or more heteroatoms in the ring(s) and optionally being aType: GrantFiled: February 1, 2006Date of Patent: May 27, 2008Assignee: The Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth Near DublinInventor: Julie A. Kelly
-
Publication number: 20070265202Abstract: The invention relates to compounds that inhibit thyrotropin-releasing hormone (TRH) degrading ectoenzyme and/or enhance, and/or mimic the biological actions of TRH. The compounds find therapeutic application, particularly in conditions involving neuronal cell injury and disturbances in neurobiological function.Type: ApplicationFiled: October 3, 2005Publication date: November 15, 2007Applicant: THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OInventor: Julie Kelly
-
Publication number: 20060293247Abstract: Peptide derivatives useful as inhibitors of activity of thyrotropin-releasing hormone-degrading ectoenzyme (TRH-DE) are of formula Ia: wherein: R1 is an optionally substituted 4-, 5- or 6-membered heterocyclic ring having one or more heteroatoms, in which at least one carbon atom of the ring is substituted with O or S; X1 is —CO— or —CS— or —CH2CO— or CH(R4) wherein R4 is H or optionally substituted alkyl or —COOH or —COOR11 wherein R11 is optionally substituted alkyl; X2 and X3 (which may be the same or different) are —CO— or —CS—; Z is —CH2— or —S—or —O— or —NH—; Q is O or S; R2 is H or optionally substituted alkyl or an optionally substituted carbocyclic ring; R3 is H or optionally substituted alkyl or an optionally substituted mono- or polycyclic ring, optionally having one or more heteroatoms in the ring(s) and optionally being a fused ring; or R2 and R3 together form an optionally substituted mono- or polycyclic ring optionally having one or more heteroatoms in the ring(s) and optionally beingType: ApplicationFiled: February 1, 2006Publication date: December 28, 2006Applicants: Elizabeth Near DublinInventor: Julie Kelly
-
Publication number: 20030166944Abstract: Peptide derivatives useful as inhibitors of activity of thyrotropin-releasing hormone-degrading ectoenzyme (TRH-DE) disclosed.Type: ApplicationFiled: August 19, 2002Publication date: September 4, 2003Applicant: The Provost, Fellows and Scholars of the College of th HolyInventor: Julie A. Kelly